Subcutaneous Drug Delivery Market & Pipeline Insight
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects.
Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can’t be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously.
Proteins are important component of several drugs which can’t be administrated through other routes like oral, intravenous or intramuscular. Protein based drugs are sensitive towards pH, extreme acidity, alkalinity and limited bioavailability causing limited number of sites for administration. For instance, insulin hormone for the treatment of Diabetes Miletus is a small protein administrated through subcutaneous route. Orally it can’t be given due to low pH of stomach which will destroy insulin; intramuscularly it will be absorbed to quickly, while intravenous administration may have potentially high life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. Subcutaneous sites are found throughout the body consisting of loose interstitial tissues that may be found in upper arm, anterior thigh surface and lower abdominal portion. These places have been found to be safe and effective for the subcutaneous drug administration.
Numerous benefits provided by innovative subcutaneous drugs and delivery devices have caused increase in their demand across the globe. Higher potency, sustained release and uniform absorption drugs from subcutaneous site has allowed patients to get more therapeutic benefits. More physicians prescribe subcutaneous drugs due to minimized side effects and new formulations are some major factors behind increased market penetration. On the other hand, subcutaneous drug delivery devices have made tremendous increase in technological aspects which is expected to gain more shares in coming years. As a result, it is expected that new innovative products with higher therapeutic capabilities will enter in market in coming years.
“Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings
Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects.
Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can’t be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously.
Proteins are important component of several drugs which can’t be administrated through other routes like oral, intravenous or intramuscular. Protein based drugs are sensitive towards pH, extreme acidity, alkalinity and limited bioavailability causing limited number of sites for administration. For instance, insulin hormone for the treatment of Diabetes Miletus is a small protein administrated through subcutaneous route. Orally it can’t be given due to low pH of stomach which will destroy insulin; intramuscularly it will be absorbed to quickly, while intravenous administration may have potentially high life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. Subcutaneous sites are found throughout the body consisting of loose interstitial tissues that may be found in upper arm, anterior thigh surface and lower abdominal portion. These places have been found to be safe and effective for the subcutaneous drug administration.
Numerous benefits provided by innovative subcutaneous drugs and delivery devices have caused increase in their demand across the globe. Higher potency, sustained release and uniform absorption drugs from subcutaneous site has allowed patients to get more therapeutic benefits. More physicians prescribe subcutaneous drugs due to minimized side effects and new formulations are some major factors behind increased market penetration. On the other hand, subcutaneous drug delivery devices have made tremendous increase in technological aspects which is expected to gain more shares in coming years. As a result, it is expected that new innovative products with higher therapeutic capabilities will enter in market in coming years.
“Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings
- Subcutaneous Drug Delivery Market Overview
- Devices for Subcutaneous Drug Delivery
- Subcutaneous Drug Delivery Market Future Prospects
- Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase
- Global Subcutaneous Drug Clinical Pipeline: 741 Drugs
- Global Marketed Subcutaneous Drugs: 228 Drugs
- Marketed Subcutaneous Drug Clinical Insight
1. INTRODUCTION TO SUBCUTANEOUS DRUG DELIVERY
2. MECHANISM OF SUBCUTANEOUS DRUG DELIVERY
3. SUBCUTANEOUS DRUG DELIVERY MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Subcutaneous Drug Delivery Pipeline Overview
4. SUBCUTANEOUS DRUG DELIVERY MARKET DYNAMICS
4.1 Favorable market Parameters
4.2 Clinical & Commercialization Challenges
5. DEVICES FOR SUBCUTANEOUS DRUG DELIVERY
5.1 Syringe Based Subcutaneous Drug Delivery
5.2 Subcutaneous Implants
5.3 Pen Systems for Subcutaneous Drug Delivery
5.4 Auto Injectors
5.5 Pump Based Drug Delivery Systems
6. SUBCUTANEOUS DRUG DELIVERY MARKET FUTURE PROSPECTS
7. SUBCUTANEOUS DRUG CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Phase: Preregistration
7.11 Phase: Registered
8. MARKETED SUBCUTANEOUS DRUG CLINICAL INSIGHT
9. DISCONTINUED & SUSPENDED SUBCUTANEOUS DRUGS IN CLINICAL TRIALS
9.1 No Development Reported
9.2 Discontinued
9.3 Preregistration-Submission Withdrawal
9.4 Market Withdrawal
9.5 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Boehringer Ingelheim
10.2 Eli Lily
10.3 Galaxo
10.4 HMD pharmaceuticals
10.5 Merck
10.6 Novartis
10.7 Novo Nordisk
10.8 Pfizer
10.9 Sanofi
10.10 Teva Pharmaceutical
10.11 Zogenix
2. MECHANISM OF SUBCUTANEOUS DRUG DELIVERY
3. SUBCUTANEOUS DRUG DELIVERY MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Subcutaneous Drug Delivery Pipeline Overview
4. SUBCUTANEOUS DRUG DELIVERY MARKET DYNAMICS
4.1 Favorable market Parameters
4.2 Clinical & Commercialization Challenges
5. DEVICES FOR SUBCUTANEOUS DRUG DELIVERY
5.1 Syringe Based Subcutaneous Drug Delivery
5.2 Subcutaneous Implants
5.3 Pen Systems for Subcutaneous Drug Delivery
5.4 Auto Injectors
5.5 Pump Based Drug Delivery Systems
6. SUBCUTANEOUS DRUG DELIVERY MARKET FUTURE PROSPECTS
7. SUBCUTANEOUS DRUG CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Phase: Preregistration
7.11 Phase: Registered
8. MARKETED SUBCUTANEOUS DRUG CLINICAL INSIGHT
9. DISCONTINUED & SUSPENDED SUBCUTANEOUS DRUGS IN CLINICAL TRIALS
9.1 No Development Reported
9.2 Discontinued
9.3 Preregistration-Submission Withdrawal
9.4 Market Withdrawal
9.5 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Boehringer Ingelheim
10.2 Eli Lily
10.3 Galaxo
10.4 HMD pharmaceuticals
10.5 Merck
10.6 Novartis
10.7 Novo Nordisk
10.8 Pfizer
10.9 Sanofi
10.10 Teva Pharmaceutical
10.11 Zogenix
LIST OF FIGURES
Figure 1-1: Functions of Skin Tissue
Figure 1-2: Different Functions of Skin Layers
Figure 1-3: Benefits of Subcutaneous Drug Delivery Site
Figure 1-4: Sites for Subcutaneous Drug Administration
Figure 1-5: Limitations of Subcutaneous Drug Delivery Site
Figure 2-1: External Factors to Increase Absorbability of Subcutaneous Drugs
Figure 2-2: Mechanism of Exogenous Insulin Administration at Subcutaneous Site
Figure 3-1: Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-2: Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-3: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-4: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-5: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-6: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-7: Suspended Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-8: Suspended Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 4-1: Drivers for Intramuscular Drug Delivery Market
Figure 4-2: Clinical & Commercialization Challenges
Figure 5-1: Classification of Subcutaneous Drug Delivery Devices
Figure 5-2: Syringe Based Subcutaneous Drug Delivery
Figure 5-3: Implant Based Subcutaneous Drug Delivery
Figure 5-4: Description of Pen Systems for Subcutaneous Drug Delivery
Figure 5-5: Benefits & Drawbacks Pen Systems for Subcutaneous Drug Delivery
Figure 5-6: Auto Injectors for Subcutaneous Drug Delivery
Figure 5-7: Different Part of Pump Based Subcutaneous Drug Delivery Device
Figure 1-1: Functions of Skin Tissue
Figure 1-2: Different Functions of Skin Layers
Figure 1-3: Benefits of Subcutaneous Drug Delivery Site
Figure 1-4: Sites for Subcutaneous Drug Administration
Figure 1-5: Limitations of Subcutaneous Drug Delivery Site
Figure 2-1: External Factors to Increase Absorbability of Subcutaneous Drugs
Figure 2-2: Mechanism of Exogenous Insulin Administration at Subcutaneous Site
Figure 3-1: Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-2: Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-3: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-4: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-5: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-6: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 3-7: Suspended Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
Figure 3-8: Suspended Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
Figure 4-1: Drivers for Intramuscular Drug Delivery Market
Figure 4-2: Clinical & Commercialization Challenges
Figure 5-1: Classification of Subcutaneous Drug Delivery Devices
Figure 5-2: Syringe Based Subcutaneous Drug Delivery
Figure 5-3: Implant Based Subcutaneous Drug Delivery
Figure 5-4: Description of Pen Systems for Subcutaneous Drug Delivery
Figure 5-5: Benefits & Drawbacks Pen Systems for Subcutaneous Drug Delivery
Figure 5-6: Auto Injectors for Subcutaneous Drug Delivery
Figure 5-7: Different Part of Pump Based Subcutaneous Drug Delivery Device
LIST OF TABLES
Table 5-1: Comparative Analysis of Different Subcutaneous Drug Delivery Systems
Table 5-1: Comparative Analysis of Different Subcutaneous Drug Delivery Systems
